Disposition of amphotericin B in the isolated perfused rat liver
- PMID: 14979999
- DOI: 10.1211/0022357022502
Disposition of amphotericin B in the isolated perfused rat liver
Abstract
The hepatic disposition and biliary excretion of amphotericin B were investigated in the isolated perfused rat liver (IPRL). Bolus dose of 50 microg, 99 microg and 198 microg amphotericin B in lipoprotein-free perfusate and 198 microg amphotericin B in perfusate with 1 microM high-density lipoprotein (HDL) or 1 microM low-density lipoprotein (LDL) were examined in the IPRL. Amphotericin B concentration in perfusate was measured using a validated HPLC assay. Amphotericin B was eliminated from the perfusate in a biexponential manner. The hepatic clearance (CL(H)) increased in proportion to the dose administered (0.27 +/- 0.05 mL min(-1) at low dose, 0.54 +/- 0.23 mL min(-1) at medium dose and 1.06 +/- 0.24 mL min(-1) at high dose), indicating non-linear hepatic disposition of amphotericin B. The hepatic extraction ratio of amphotericin B was very low (0.066 +/- 0.015). Tissue-to-perfusion partition coefficient, calculated at 120 min, increased 1.5 fold from 9.8 +/- 1.7 at low dose to 15.9 +/- 6.4 at high dose, suggesting the significant uptake and extensive retention of amphotericin B in the liver. Biliary excretion made only minor contribution to amphotericin B elimination in the IPRL, representing around 1-3% of the dose administered. No metabolites were detected in perfusate, bile and liver samples. The hepatic disposition of amphotericin B was not affected by the presence of HDL and LDL in the perfusate. In conclusion, the hepatic disposition of amphotericin B demonstrates restrictive elimination and is concentration-dependent, consistent with carrier-mediated uptake, and lipoproteins do not influence amphotericin B hepatobiliary disposition.
Similar articles
-
Hepatobiliary disposition of liposomal amphotericin B in the isolated perfused rat liver.J Pharm Sci. 2005 Jan;94(1):169-76. doi: 10.1002/jps.20239. J Pharm Sci. 2005. PMID: 15761940
-
Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide.Clin Exp Pharmacol Physiol. 2006 Aug;33(8):685-9. doi: 10.1111/j.1440-1681.2006.04419.x. Clin Exp Pharmacol Physiol. 2006. PMID: 16895540
-
Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver.Drug Metab Dispos. 1996 Sep;24(9):984-9. Drug Metab Dispos. 1996. PMID: 8886608
-
Corticosteroid metabolism in isolated perfused rat liver and kidney. Experimental studies with emphasis on aldosterone.Acta Physiol Scand Suppl. 1995;627:1-42. Acta Physiol Scand Suppl. 1995. PMID: 8848946 Review.
-
[Drug dosing in chronic hepatic disease (author's transl)].Leber Magen Darm. 1981 Apr;11(2):81-7. Leber Magen Darm. 1981. PMID: 7015045 Review. German.
Cited by
-
Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases.Eur J Clin Pharmacol. 2007 Feb;63(2):165-72. doi: 10.1007/s00228-006-0240-x. Epub 2006 Dec 19. Eur J Clin Pharmacol. 2007. PMID: 17180621 Clinical Trial.
-
Influence of kavain on hepatic ultrastructure.World J Gastroenterol. 2008 Jan 28;14(4):541-6. doi: 10.3748/wjg.14.541. World J Gastroenterol. 2008. PMID: 18203285 Free PMC article.
-
Assessment and histological analysis of the IPRL technique for sequential in situ liver biopsy.Comp Hepatol. 2011 Aug 8;10:7. doi: 10.1186/1476-5926-10-7. Comp Hepatol. 2011. PMID: 21819626 Free PMC article.
-
Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition.Pharm Res. 2014 Jan;31(1):35-45. doi: 10.1007/s11095-013-1127-z. Epub 2013 Jun 21. Pharm Res. 2014. PMID: 23793994
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous